Yan Lu, Jiahui Lan, Ling Bi and Ling Xu*
HER-2 amplification is a rare mutation and potential target in the treatment of pulmonary adenocarcinoma (AC). Clinical efficacy of HER-2 targeted agent has been reported for AC with HER-2 exon 20 insertions; however it remains unknown for those with HER-2 amplification. Here we report a case of advanced AC harboring HER-2 amplification treated with afatinib, and objective response and symptom improvement were observed.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 